Arrayit Corporation (ARYC)

[MikeCr]

Good analysis Silver. I'm surprised that EarlyCDT-Lung™ will be launched nationally in the USA this month considering it has not been approved by the FDA.

Oncimmune plans to adapt this technology to the development of blood tests for a variety of solid tumor cancers. The next test to follow EarlyCDT–Lung™ to the market will be a blood test to aid in early detection of breast cancer. The EarlyCDT–Breast test is in advanced stages of development and will be launched in 2011.

In addition to the EarlyCDT–Breast test, the company has also completed proof-of-principle studies on other tumor types (e.g., ovarian, esophago-gastric, colon and liver cancers) and plans to start validation of tests for these other types of cancer over the next two years.

Presentations on the technology are due to be made at the American Society of Clinical Oncology’s annual conference in Chicago next week. The same conference where the MD Anderson ovarian cancer study is being presented. IMO Arrayit should have presented their technology there also.

Arrayit's OvaDX is still kind of a "black box" test. It should be superior but we don't know too much detail about it. Have they ever identified the 100 biomarkers that they use? Also the clinical data is scant. Hopefully it all will become more clear when they apply to the FDA and present the data.